All In Biotech

Drug Trial Radar · NCT07925983

A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult Participants

A Phase 1 Study in Healthy Subjects to Assess Pharmacokinetics Following Intravenous and Subcutaneous Administration of Trosunilimab

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 13, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the pharmacokinetic (PK), immunogenicity and safety following trosunilimab SC and trosunilimab IV doses in healthy adult participants.

Conditions

  • Healthy Volunteer

Interventions

  • TrosunilimabDrug

    Subcutaneous (SC) Injection

  • TrosunilimabDrug

    Intravenous (IV) Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Serum Concentration (Cmax) of trosunilimabTime frame: Up to 7 Days
  2. Time to Cmax (Tmax) of trosunilimabTime frame: Up to 7 Days
  3. Concentration at Week 4 (Cwk4) of trosunilimabTime frame: Week 4
  4. Area under the serum concentration-time curve from Week 0 to 4 (AUC0-4wk) of trosunilimabTime frame: Weeks 0 to 4
  5. Number of Participants Experiencing Adverse EventsTime frame: Up to 140 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Acpru /Id# 286224

    Grayslake, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.